

Clozapine-related tachycardia: An analysis of incidence Supplementary files

Journal: CNS Drugs

Authors: Susanna Every-Palmer^{*1,2}, Korinne Northwood^{*3,4,5}, James Tsakas⁶, Matthew K Burrage^{5,7},
Dan Siskind^{#3,4,5}

* Joint first authors

Corresponding author

Corresponding author contact details: Professor Dan Siskind, PA Southside Clinical Unit, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, Queensland, Australia. d.siskind@uq.edu.au

Supplementary Table 1. Participant characteristic by baseline HR group

	Baseline HR Group						P-value*
	60–70bpm	71–80bpm	81–90bpm	91–100bpm	>100bpm	Overall	
	(N=14)	(N=38)	(N=36)	(N=29)	(N=6)	(N=123)	
Age (years)							0.95
Mean (SD)	39.6 (13.8)	36.9 (11.7)	36.4 (12.6)	36.3 (10.4)	34.5 (9.09)	36.8 (11.7)	-
Median [Min, Max]	38.0 [21.0, 76.0]	36.0 [19.0, 58.0]	32.0 [18.0, 68.0]	37.0 [19.0, 56.0]	35.0 [23.0, 49.0]	36.0 [18.0, 76.0]	-
Age group (years)							0.8
18–24	1 (7.1%)	8 (21.1%)	5 (13.9%)	6 (20.7%)	1 (16.7%)	21 (17.1%)	-
25–34	4 (28.6%)	9 (23.7%)	16 (44.4%)	5 (17.2%)	2 (33.3%)	36 (29.3%)	-
35–44	4 (28.6%)	10 (26.3%)	7 (19.4%)	11 (37.9%)	2 (33.3%)	34 (27.6%)	-
45–54	4 (28.6%)	9 (23.7%)	4 (11.1%)	5 (17.2%)	1 (16.7%)	23 (18.7%)	-
55–64	0 (0%)	2 (5.3%)	3 (8.3%)	2 (6.9%)	0 (0%)	7 (5.7%)	-
65+	1 (7.1%)	0 (0%)	1 (2.8%)	0 (0%)	0 (0%)	2 (1.6%)	
Gender							0.16
F	4 (28.6%)	11 (28.9%)	14 (38.9%)	16 (55.2%)	1 (16.7%)	46 (37.4%)	-
M	10 (71.4%)	27 (71.1%)	22 (61.1%)	13 (44.8%)	5 (83.3%)	77 (62.6%)	-
BMI							0.48
Mean (SD)	29.2 (5.57)	28.4 (6.12)	31.8 (9.33)	29.7 (5.62)	32.8 (9.56)	30.0 (7.27)	-
Median [Min, Max]	28.6 [21.2, 42.4]	27.5 [18.7, 44.0]	30.2 [16.6, 54.7]	28.7 [19.4, 47.7]	31.5 [23.4, 47.6]	28.7 [16.6, 54.7]	-
Missing	0 (0%)	0 (0%)	0 (0%)	2 (6.9%)	1 (16.7%)	3 (2.4%)	-
BMI >30							0.69
No	8 (57.1%)	24 (63.2%)	18 (50.0%)	17 (58.6%)	2 (33.3%)	69 (56.1%)	-
Yes	6 (42.9%)	14 (36.8%)	18 (50.0%)	10 (34.5%)	3 (50.0%)	51 (41.5%)	-
Missing	0 (0%)	0 (0%)	0 (0%)	2 (6.9%)	1 (16.7%)	3 (2.4%)	-
Ethnicity							0.17
Aboriginal not Torres Strait Islander	1 (7.1%)	2 (5.3%)	1 (2.8%)	3 (10.3%)	1 (16.7%)	8 (6.5%)	-
Asian	1 (7.1%)	8 (21.1%)	1 (2.8%)	3 (10.3%)	1 (16.7%)	14 (11.4%)	-
Caucasian	9 (64.3%)	24 (63.2%)	25 (69.4%)	17 (58.6%)	4 (66.7%)	79 (64.2%)	-
Pacific Islander	1 (7.1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0.8%)	-
Māori	1 (7.1%)	0 (0%)	1 (2.8%)	0 (0%)	0 (0%)	2 (1.6%)	-
African	0 (0%)	1 (2.6%)	2 (5.6%)	3 (10.3%)	0 (0%)	6 (4.9%)	-
Indian	0 (0%)	0 (0%)	1 (2.8%)	0 (0%)	0 (0%)	1 (0.8%)	-
Torres Strait Islander not Aboriginal	0 (0%)	0 (0%)	0 (0%)	1 (3.4%)	0 (0%)	1 (0.8%)	-
Missing	1 (7.1%)	3 (7.9%)	5 (13.9%)	2 (6.9%)	0 (0%)	11 (8.9%)	-
Ever smoked							0.11
No	8 (57.1%)	19 (50.0%)	15 (41.7%)	6 (20.7%)	3 (50.0%)	51 (41.5%)	-
Yes	6 (42.9%)	19 (50.0%)	19 (52.8%)	20 (69.0%)	3 (50.0%)	67 (54.5%)	-

Missing	0 (0%)	0 (0%)	2 (5.6%)	3 (10.3%)	0 (0%)	5 (4.1%)	-
Cigarettes per day							-
Mean (SD)	19.2 (9.17)	15.9 (6.43)	23.9 (8.67)	16.9 (5.53)	23.3 (11.5)	19.1 (7.92)	0.034
Median [Min, Max]	17.5 [10.0, 30.0]	15.0 [10.0, 30.0]	20.0 [10.0, 40.0]	20.0 [10.0, 30.0]	30.0 [10.0, 30.0]	20.0 [10.0, 40.0]	-

*Kruskal-Wallis test, ** Wilcoxon test

bpm = beats per minute; HR = Heart rate, SD = standard deviation


Supplementary Table 2. Change in heart rate at Day 14 and Day 28 of clozapine titration

	Baseline HR group						p-value*
	60-70	71-80	81-90	91-100	>100	Overall	
	(N=14)	(N=38)	(N=36)	(N=29)	(N=6)	(N=123)	
Baseline HR (bpm)							
Mean (SD)	66.7 (2.93)	76.4 (2.84)	85.0 (2.33)	95.5 (2.78)	105 (2.10)	83.7 (10.6)	
Median [Min, Max]	67.3 [62.0, 70.3]	76.5 [71.0, 80.7]	85.0 [81.3, 90.3]	95.7 [91.0, 100]	105 [102, 108]	83.0 [62.0, 108]	
Day 14 HR (bpm)							
Mean (SD)	92.1 (10.9)	100 (9.34)	101 (10.4)	104 (7.01)	110 (4.80)	101 (9.89)	0.00037
Median [Min, Max]	94.0 [74.3, 114]	99.8 [74.0, 121]	101 [82.3, 122]	103 [91.7, 122]	110 [105, 119]	100 [74.0, 122]	
Day 14 Change in HR (bpm)							
Mean (SD)	25.4 (11.9)	23.8 (9.57)	16.1 (10.1)	8.26 (7.51)	5.17 (6.21)	17.2 (11.6)	<0.0001
Median [Min, Max]	24.8 [7.00, 52.0]	23.0 [2.67, 47.7]	16.2 [-0.333, 37.3]	8.67 [-7.00, 28.3]	3.50 [0, 17.3]	17.3 [-7.00, 52.0]	
Day 28 HR (bpm)							
Mean (SD)	92.3 (4.28)	96.9 (8.88)	103 (8.21)	103 (7.15)	111 (6.47)	101 (8.82)	<0.0001
Median [Min, Max]	90.8 [85.3, 97.0]	95.5 [75.3, 115]	104 [87.0, 116]	101 [94.3, 117]	111 [103, 119]	100 [75.3, 119]	
Missing	6 (42.9%)	16 (42.1%)	9 (25.0%)	7 (24.1%)	2 (33.3%)	40 (32.5%)	
Day 28 Change in HR (bpm)							
Mean (SD)	25.1 (4.82)	20.7 (9.72)	18.0 (8.09)	7.61 (7.67)	6.50 (5.65)	16.1 (10.1)	<0.0001
Median [Min, Max]	22.8 [20.7, 34.3]	20.2 [-5.00, 35.3]	17.3 [5.33, 32.0]	5.50 [-1.33, 23.0]	7.17 [-1.00, 12.7]	16.7 [-5.00, 35.3]	
Missing	6 (42.9%)	16 (42.1%)	9 (25.0%)	7 (24.1%)	2 (33.3%)	40 (32.5%)	
p-value**: Baseline vs Day 14	0.0011	<0.0001	<0.0001	<0.0001	0.031	< 0.0001	
p-value**: Baseline vs Day 28	0.0078	<0.0001	<0.0001	<0.0001	0.25	<0.0001	

*Kruskal-Wallis test, ** Wilcoxon test

bpm = beats per minute; HR = Heart rate, SD = standard deviation

Supplementary Fig 3.



Heart rate plotted against clozapine serum level (ug/L)